Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVGRNASDAQ:NVIVNASDAQ:TTOONASDAQ:VERO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$2.01$1.57M1.291.30 million shsN/ANVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsTTOOT2 Biosystems$0.15+7.1%$0.14$0.06▼$6.00$3.15M0.48579,868 shs24,670 shsVEROVenus Concept$2.20+0.9%$2.42$2.10▼$14.50$3.11M0.07609,616 shs33,125 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%0.00%-75.57%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%TTOOT2 Biosystems+7.46%+9.50%+1.22%+36.03%-97.20%VEROVenus Concept+0.92%-8.71%-4.35%-20.00%-75.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVGRAvingerN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATTOOT2 Biosystems1.5458 of 5 stars3.03.00.00.00.00.00.0VEROVenus Concept2.9944 of 5 stars0.05.00.00.04.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger 0.00N/AN/AN/ANVIVInVivo Therapeutics 0.00N/AN/AN/ATTOOT2 Biosystems 2.00Hold$5.003,235.56% UpsideVEROVenus Concept 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.65M0.21N/AN/A($4.53) per share-0.10NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ATTOOT2 Biosystems$7.68M0.41N/AN/A($6.91) per share-0.02VEROVenus Concept$64.83M0.05N/AN/A$4.30 per share0.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$11.06N/AN/AN/A-261.06%-5,527.11%-123.25%8/6/2025 (Estimated)NVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ATTOOT2 Biosystems-$50.08MN/A0.00∞N/A-563.16%N/A-174.06%7/28/2025 (Estimated)VEROVenus Concept-$47M-$76.30N/A∞N/A-81.26%-752.29%-54.52%8/12/2025 (Estimated)Latest NVIV, VERO, TTOO, and AVGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025VEROVenus Concept-$14.08-$17.44-$3.36-$17.44$14.59 million$13.64 million3/31/2025Q4 2024VEROVenus Concept-$10.0089-$11.23-$1.2211-$11.23$16.99 million$15.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/AVEROVenus ConceptN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/A1.210.81NVIVInVivo TherapeuticsN/A14.3014.30TTOOT2 BiosystemsN/A0.400.24VEROVenus Concept7.911.280.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%NVIVInVivo Therapeutics13.78%TTOOT2 Biosystems23.18%VEROVenus Concept87.41%Insider OwnershipCompanyInsider OwnershipAVGRAvinger42.80%NVIVInVivo Therapeutics2.45%TTOOT2 Biosystems0.03%VEROVenus Concept28.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger703.31 million1.89 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableTTOOT2 Biosystems18021.04 million21.04 millionOptionableVEROVenus Concept4101.42 million1.03 millionNot OptionableNVIV, VERO, TTOO, and AVGR HeadlinesRecent News About These CompaniesVenus Concept Inc News (VERO) - Investing.comJune 26 at 6:05 PM | investing.comVenus Concept Inc. (NASDAQ:VERO) Sees Significant Drop in Short InterestJune 17, 2025 | americanbankingnews.comVenus Concept Stock Climbs After Stock Offering ClosesJune 9, 2025 | marketwatch.comVenus Concept Inc. Closes Registered Direct Offering and Private Placement Raising Approximately $1.15 MillionJune 9, 2025 | quiverquant.comQVenus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesJune 9, 2025 | globenewswire.comVenus Concept To Sell Hair Business To Meta Healthcare In $20M All-Cash DealJune 8, 2025 | nasdaq.comVenus Concept prices $3.45M in direct offering, warrants; shares up over 29%June 7, 2025 | msn.comVenus Concept Stock Is Soaring On Friday - Here's WhyJune 7, 2025 | aol.comAVenus Concept Sells Hair Business to Meta HealthcareJune 6, 2025 | tipranks.comVenus Concept Stock Is Soaring On Friday - Here's WhyJune 6, 2025 | benzinga.comVenus Concept Inc.: Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 MillionJune 6, 2025 | finanznachrichten.deVenus Concept Shares Soar on Sale of Hair BusinessJune 6, 2025 | marketwatch.comVenus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesJune 6, 2025 | globenewswire.comVenus Concept Inc. Sells Venus Hair Business to Meta Healthcare Group in $20 Million DealJune 6, 2025 | quiverquant.comQVenus Concept to sell Venus Hair business for $20M, stock soars 50%June 6, 2025 | msn.comVenus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 MillionJune 6, 2025 | globenewswire.comVenus Concept Announces First Quarter 2025 Financial ResultsMay 16, 2025 | theglobeandmail.comVenus Concept Inc (VERO) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines Amid ...May 16, 2025 | finance.yahoo.comVenus Concept Inc. (NASDAQ:VERO) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comVenus Concept Inc. (VERO) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVIV, VERO, TTOO, and AVGR Company DescriptionsAvinger NASDAQ:AVGR$0.47 0.00 (0.00%) As of 06/25/2025Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.InVivo Therapeutics NASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.T2 Biosystems NASDAQ:TTOO$0.15 +0.01 (+7.07%) As of 06/26/2025 03:10 PM EasternT2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Venus Concept NASDAQ:VERO$2.20 +0.02 (+0.92%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.20 +0.00 (+0.23%) As of 06/26/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
